Evidence map›Paper›PMID 40225749›Full record

ArticleJournal of tissue engineering and regenerative medicine2024

Bilateral Crosslinking with Glutaraldehyde and 1-Ethyl-3-(3-Dimethylaminopropyl) Carbodiimide: An Optimization Strategy for the Application of Decellularized Human Amniotic Membrane in Tissue Engineering.

Fatemeh Alibabaei-Omran, Ebrahim Zabihi, Alexander M Seifalian, Nima Javanmehr, Ali Samadikuchaksaraei, Mazaher Gholipourmalekabadi, Mohammad Hossein Asghari, Hamid Reza Nouri, Roghayeh Pourbagher, Zinatossadat Bouzari and 1 more

Abstract read
In one paragraph

Article in Journal of tissue engineering and regenerative medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Fatemeh Alibabaei-OmranCellular and Molecular Biology Research Center, Babol University of Medical Sciences, Babol, Iran.
Ebrahim ZabihiCellular and Molecular Biology Research Center, Babol University of Medical Sciences, Babol, Iran.ORCID https://orcid.org/0000-0003-4210-3836
Alexander M SeifalianNanotechnology & Regenerative Medicine Commercialization Centre (NanoRegMed Ltd., Nano Loom Ltd., & Librium Health Ltd.), London Bioscience Innovation Centre, London, UK.
Nima JavanmehrStudent Research Committee, Babol University of Medical Sciences, Babol, Iran.
Ali SamadikuchaksaraeiDepartment of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran.
Mazaher GholipourmalekabadiDepartment of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran.
Mohammad Hossein AsghariCellular and Molecular Biology Research Center, Babol University of Medical Sciences, Babol, Iran.
Hamid Reza NouriCellular and Molecular Biology Research Center, Babol University of Medical Sciences, Babol, Iran.
Roghayeh PourbagherCellular and Molecular Biology Research Center, Babol University of Medical Sciences, Babol, Iran.
Zinatossadat BouzariDepartment of Gynaecology and Obstetrics, Babol University of Medical Sciences, Babol, Iran.
Seyedali SeyedmajidiDental Materials Research Center, Babol University of Medical Sciences, Babol, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The decellularized human amniotic membrane (dHAM) emerges as a viable 3D scaffold for organ repair and replacement using a tissue engineering strategy. Glutaraldehyde (GTA) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) can increase the biomechanical properties of dHAM. However, the crosslinking process is associated with biochemical changes and residual toxic materials, dampening the biocompatibility of the dHAM. From a histologic point of view, each side of the amniotic membrane is biologically different. While the dHAM basement membrane side is rich in growth factors, the stromal side of the dHAM contains more connective tissue matrix (e.g., collagen fibers) which supports its biomechanical properties. Biocompatibility and biomechanical properties are two important challenges in the field of materials science. In this study, for the first time, the stromal and basement membrane side are cross-linked with GTA and EDC, respectively, to optimize the biocompatibility of the treated dHAM while sparing the GTA-mediated biomechanical improvements. Methods: Crosslinking was carried out on dHAM in three groups: EDC, GTA and bilateral treatment with EDC&GTA. Mechanical resistance, degradability, and crosslinking measurements were performed on treated dHAM. The viability of mesenchymal stem cells (MSCs) on the scaffolds was evaluated by the MTT assay. The expression levels of surface markers and images of the MSCs were thoroughly studied. Results: The results obtained showed that bilateral treatment of dHAM with EDC and GTA increased mechanical resistance. Similarly, the evaluation of surface markers revealed that bilaterally treated dHAM sustains the stemness and viability of MSCs at a level equal to that achieved with EDC alone. The SEM images indicated that the MSCs maintained adhesion on EDC&GTA-cross-linked dHAM. Conclusion: The current study explores a pioneering treatment of dHAM, a material long recognized for its regenerative properties, in a novel context. This research delves into the utilization of dHAM cross-linked with EDC&GTA, demonstrating its optimized efficacy in tissue engineering. The enhanced crosslinking technique significantly alters the membrane's properties, amplifying its durability and therapeutic potential. In this novel bilateral treatment strategy (EDC and GTA), improving mechanical properties by GTA on the stromal surface and maintaining the biocompatibility of EDC on the side of the basement membrane of dHAM had been attained together. By investigating the handling and impact of this cross-linked membrane, this study unveils a new approach in leveraging a well-known material through an innovative process, revolutionizing its application in wound care.

Indexed as

AmnionCarbodiimidesCross-Linking ReagentsEthyldimethylaminopropyl CarbodiimideGlutaralTissue EngineeringBiomechanical PhenomenaHumansMesenchymal Stem CellsTissue ScaffoldsCarbodiimidesCross-Linking ReagentsEthyldimethylaminopropyl CarbodiimideGlutaral

Identifiers

PMID40225749
PMCPMC11919163

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.